{"uid":"cap_OQwLiEZLtO10srssSxPph","slug":"clinical-trials-search-the-stall-x402-498ec228","name":"Clinical Trials Search — The Stall x402","description":"Search ClinicalTrials.gov for clinical studies by condition, intervention, or keyword. Returns phase, status, enrollment, sponsor, and dates. NIH primary source — no markup. $0.005/call.","url":"https://the-stall.intuitek.ai/cap/clinical-trials","method":"GET","headers":{},"bodySchema":{"type":"object","properties":{"required":{"type":"string"},"properties":{"type":"string"}}},"responseSchema":null,"example":{"request":{"input":{"type":"http","method":"GET","queryParams":{"limit":10,"status":"recruiting","condition":"diabetes"}}},"response":{"ts":"2026-06-19T05:52:58.076Z","query":{"phase":null,"status":"recruiting","sponsor":null,"condition":"diabetes","intervention":null},"studies":[{"url":"https://clinicaltrials.gov/study/NCT07372157","phase":"NA","title":"Neuromuscular Balance Exercise Effects in Overweight and Obese Individuals","nct_id":"NCT07372157","status":"RECRUITING","conditions":["Overweight and Obesity"],"enrollment":40,"start_date":"2025-06-15","study_type":"INTERVENTIONAL","lead_sponsor":"Marmara University","brief_summary":"This randomized controlled study aims to evaluate the effects of adding neuromuscular balance exercises to exercise programs on functional capacity, balance, and physical fitness in individuals with obesity. Forty participants will be randomly assigned to either a control group receiving aerobic and strength training exercises or an intervention group receiving aerobic and strength training combined with neuromuscular balance exercises. Both exercise programs will be conducted three times per we","interventions":["Aerobic and strength training","Neuromuscular balance exercises"],"completion_date":"2026-06"},{"url":"https://clinicaltrials.gov/study/NCT04799301","phase":"PHASE1","title":"Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake","nct_id":"NCT04799301","status":"RECRUITING","conditions":["Diet Therapy","Healthy Volunteers"],"enrollment":60,"start_date":"2022-02-23","study_type":"INTERVENTIONAL","lead_sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","brief_summary":"Background: Diet is one of the most modifiable behaviors affecting health. But diet assessment measures that are based on self-report can be inaccurate. Researchers want better ways to address the role of diet in chronic disease. They want to see if stable isotopes can be used to better assess what people eat. Objective: To see if stable isotopes can help scientists identify things people eat. Eligibility: Healthy adults ages 18 to 65 Design: Participants will be screened with a medical history ","interventions":["Diet with no soda","Diet with 50% of carb intake from soda","Diet with 20% of carb intake from soda"],"completion_date":"2028-01-01"},{"url":"https://clinicaltrials.gov/study/NCT05363761","phase":"PHASE1","title":"Arterial Ablation for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities","nct_id":"NCT05363761","status":"RECRUITING","conditions":["Diabetes Mellitus, Type 2","Hypertension"],"enrollment":50,"start_date":"2022-04-19","study_type":"INTERVENTIONAL","lead_sponsor":"Neurotronic, Inc.","brief_summary":"This study is assess the safety and performance of the Neurotronic Infusion catheter for treatment of patients with Type 2 Diabetes (T2DM) and hypertension.","interventions":["Neurotronic Infusion Catheter"],"completion_date":"2025-01"},{"url":"https://clinicaltrials.gov/study/NCT07634770","phase":"PHASE1","title":"Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin","nct_id":"NCT07634770","status":"RECRUITING","conditions":["Diabetes Mellitus, Type 1"],"enrollment":16,"start_date":"2026-05-29","study_type":"INTERVENTIONAL","lead_sponsor":"Sam Chun Dang Pharm. Co. Ltd.","brief_summary":"Reason for the study The participants have been diagnosed with type 1 diabetes and are being treated with standard insulin therapy. The sponsor of the study is developing a new insulin-based medicine that can be taken by mouth (orally). For this reason, the investigational product named SCD0503 is to be tested in the study. The sponsor wants to investigate the course of blood concentrations and the blood sugar-lowering effect of the investigational product and to find out whether SCD0503 is safe","interventions":["oral insulin","Placebo A","subcutaneous insulin","Placebo B"],"completion_date":"2026-10"},{"url":"https://clinicaltrials.gov/study/NCT04058639","phase":"NA","title":"Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?","nct_id":"NCT04058639","status":"RECRUITING","conditions":["Diabetic Foot Ulcer"],"enrollment":74,"start_date":"2019-10-01","study_type":"INTERVENTIONAL","lead_sponsor":"Helse Møre og Romsdal HF","brief_summary":"The Surgical Outpatient Clinic at Molde Hospital has since 2015 offered specialized treatment for patients with diabetic foot ulcers. This treatment is given by an interdisciplinary diabetic foot ulcer team. The standard treatment for diabetic foot ulcers is relief, a method with good results. Although the treatment as usual gives good results, the team wants to optimize this treatment. By using custom felt relief for each patient, the treatment period might be reduced considerably. The aim of t","interventions":["\"custom felt relief\"","standard relief treatment"],"completion_date":"2026-03-01"},{"url":"https://clinicaltrials.gov/study/NCT06823466","phase":null,"title":"Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants","nct_id":"NCT06823466","status":"RECRUITING","conditions":["Ischemic Stroke","Oral Anticoagulation","Atrial Fibrillation (AF)","Outcome Assessment","Clinical Presentations"],"enrollment":200,"start_date":"2025-02-12","study_type":"OBSERVATIONAL","lead_sponsor":"University of L'Aquila","brief_summary":"The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or other cardioembolic arrhythmias and to characterize short and long-term outcomes associated with different secondary prevention strategies to prevent stroke recurrences. The ASPERA study is a multicenter, observational, both retrospective and prospective real-world study","interventions":[],"completion_date":"2027-02-12"},{"url":"https://clinicaltrials.gov/study/NCT05307731","phase":"PHASE4","title":"Fingolimod for Type 2 Diabetes Mellitus","nct_id":"NCT05307731","status":"RECRUITING","conditions":["Diabetes Mellitus, Type 2"],"enrollment":40,"start_date":"2022-03-15","study_type":"INTERVENTIONAL","lead_sponsor":"General Hospital of Shenyang Military Region","brief_summary":"The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .","interventions":["Fingolimod","guideline-based treatment for DM"],"completion_date":"2026-03-15"},{"url":"https://clinicaltrials.gov/study/NCT05451901","phase":"NA","title":"Immediate Necrosectomy vs. Step-up Approach for Walled-off Necrosis","nct_id":"NCT05451901","status":"RECRUITING","conditions":["Pancreatic Fluid Collection","Walled-off Necrosis","Pancreatitis, Acute Necrotizing","Pancreatic Pseudocyst"],"enrollment":70,"start_date":"2022-07-29","study_type":"INTERVENTIONAL","lead_sponsor":"Tokyo University","brief_summary":"Walled-off necrosis (WON) is a pancreatic fluid collection, which contains necrotic tissue after four weeks of the onset of acute pancreatitis. Interventions are required to manage patients with infected WON, for which endoscopic ultrasonography (EUS)-guided drainage has become a first-line treatment modality. For patients who are refractory to EUS-guided drainage, the step-up treatment including endoscopic necrosectomy (EN) and/or additional drainage is considered to subside the infection. Rece","interventions":["Immediate necrosectomy","Step-up approach"],"completion_date":"2025-04-01"},{"url":"https://clinicaltrials.gov/study/NCT07381257","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Rifaximin-α in Treating MASLD","nct_id":"NCT07381257","status":"RECRUITING","conditions":["Metabolic Dysfunction-Associated Steatotic Liver Disease"],"enrollment":60,"start_date":"2026-01-15","study_type":"INTERVENTIONAL","lead_sponsor":"Shanghai Changzheng Hospital","brief_summary":"Study Objective: To evaluate the efficacy and safety of Rifaximin-α in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and investigate the underlying mechanisms by which Rifaximin-α influences MASLD progression. Target Population: Patients diagnosed with MASLD. Intervention: This trial is a multicenter, prospective, randomized, controlled study. Enrolled MASLD patients who meet the inclusion criteria, do not meet any exclusion criteria, and provide written info","interventions":["Rifaximin-α (Alfa Wassermann S.p.A., Italy)"],"completion_date":"2027-12-31"},{"url":"https://clinicaltrials.gov/study/NCT07336914","phase":"NA","title":"Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes","nct_id":"NCT07336914","status":"RECRUITING","conditions":["Gestational Diabetes"],"enrollment":60,"start_date":"2025-10-01","study_type":"INTERVENTIONAL","lead_sponsor":"Khyber Medical University Peshawar","brief_summary":"This study involved two management protocols to manage diabetes in pregnancy. Sixty patients having GDM will be recruited on the basis of the OGTT and randomly allocated to two management groups. One group of patients will receive counselling and the conventional method of management. while the other group will receive a tailored diet plan and physical activity with low caloric and moderate intense exercises. Both groups will receive a dietary plan based on their sugar levels weekly basis and ph","interventions":["Dietary intervention + Physical Activity + Monitoring","Usual care"],"completion_date":"2026-03-30"}],"returned":10,"total_found":10}},"exampleRequest":{"limit":10,"status":"recruiting","condition":"diabetes"},"tags":["x402"],"displayCostAmount":"0.005","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"settled","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.005/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.034","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.034","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_0F-LHUWdbXxPIRb9lSu6s","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.034","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Search active and historical clinical trials by condition, phase, status, sponsor, or intervention using the ClinicalTrials.gov data feed, paid per-call with USDC.","exampleAgentPrompt":"Find me up to 20 currently recruiting phase 3 clinical trials for lung cancer, and filter by the intervention 'pembrolizumab' — show me what's out there.","exampleUseCases":null,"resultDescription":"A list of up to 50 clinical trial records matching the query, including trial identifiers, title, phase, recruitment status, sponsor, interventions, and conditions. Results are drawn from ClinicalTrials.gov data.","failureModes":["No trials found for obscure or misspelled condition — returns empty results","Invalid phase enum value — schema validation error","Condition parameter missing — request rejected as required field","Limit exceeds 50 — clamped or rejected","Payment failure via x402 — 402 response with payment details required","Upstream ClinicalTrials.gov API unavailable — 503 or timeout"],"whenToPreferThis":"Use this endpoint when an agent needs to search clinical trial data programmatically without setting up API keys or accounts, and is willing to pay $0.005 USDC per call. Ideal for healthcare research assistants, patient-facing agents looking for trial eligibility, or pharma/biotech research workflows. Prefer over direct ClinicalTrials.gov API if payment-native x402 flow is already in use.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T00:52:49.366Z","isFirstParty":false}